Targeting cellular senescence prevents age-related bone loss in mice

Joshua Farr, Ming Xu, Megan Weivoda, David G Monroe, Daniel G. Fraser, Jennifer L. Onken, Brittany A. Negley, Jad G. Sfeir, Mikolaj B. Ogrodnik, Christine M. Hachfeld, Nathan K LeBrasseur, Matthew M Drake, Robert Pignolo, Tamar Pirtskhalava, Tamara Tchkonia, Merry Jo Oursler, James L Kirkland, Sundeep Khosla

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Aging is associated with increased cellular senescence, which is hypothesized to drive the eventual development of multiple comorbidities. Here we investigate a role for senescent cells in age-related bone loss through multiple approaches. In particular, we used either genetic (i.e., the INK-ATTAC 'suicide' transgene encoding an inducible caspase 8 expressed specifically in senescent cells) or pharmacological (i.e., 'senolytic' compounds) means to eliminate senescent cells. We also inhibited the production of the proinflammatory secretome of senescent cells using a JAK inhibitor (JAKi). In aged (20-to 22-month-old) mice with established bone loss, activation of the INK-ATTAC caspase 8 in senescent cells or treatment with senolytics or the JAKi for 2-4 months resulted in higher bone mass and strength and better bone microarchitecture than in vehicle-Treated mice. The beneficial effects of targeting senescent cells were due to lower bone resorption with either maintained (trabecular) or higher (cortical) bone formation as compared to vehicle-Treated mice. In vitro studies demonstrated that senescent-cell conditioned medium impaired osteoblast mineralization and enhanced osteoclast-progenitor survival, leading to increased osteoclastogenesis. Collectively, these data establish a causal role for senescent cells in bone loss with aging, and demonstrate that targeting these cells has both anti-resorptive and anabolic effects on bone. Given that eliminating senescent cells and/or inhibiting their proinflammatory secretome also improves cardiovascular function, enhances insulin sensitivity, and reduces frailty, targeting this fundamental mechanism to prevent age-related bone loss suggests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbidities.

Original languageEnglish (US)
Pages (from-to)1072-1079
Number of pages8
JournalNature Medicine
Volume23
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Cell Aging
Osteoporosis
Bone
Bone and Bones
Caspase 8
Transgenic Suicide Genes
Osteogenesis
Comorbidity
Aging of materials
Anabolic Agents
Osteoblasts
Conditioned Culture Medium
Osteoclasts
Bone Resorption
Insulin Resistance
Chemical activation
Insulin
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Targeting cellular senescence prevents age-related bone loss in mice. / Farr, Joshua; Xu, Ming; Weivoda, Megan; Monroe, David G; Fraser, Daniel G.; Onken, Jennifer L.; Negley, Brittany A.; Sfeir, Jad G.; Ogrodnik, Mikolaj B.; Hachfeld, Christine M.; LeBrasseur, Nathan K; Drake, Matthew M; Pignolo, Robert; Pirtskhalava, Tamar; Tchkonia, Tamara; Oursler, Merry Jo; Kirkland, James L; Khosla, Sundeep.

In: Nature Medicine, Vol. 23, No. 9, 01.09.2017, p. 1072-1079.

Research output: Contribution to journalArticle

Farr, J, Xu, M, Weivoda, M, Monroe, DG, Fraser, DG, Onken, JL, Negley, BA, Sfeir, JG, Ogrodnik, MB, Hachfeld, CM, LeBrasseur, NK, Drake, MM, Pignolo, R, Pirtskhalava, T, Tchkonia, T, Oursler, MJ, Kirkland, JL & Khosla, S 2017, 'Targeting cellular senescence prevents age-related bone loss in mice', Nature Medicine, vol. 23, no. 9, pp. 1072-1079. https://doi.org/10.1038/nm.4385
Farr, Joshua ; Xu, Ming ; Weivoda, Megan ; Monroe, David G ; Fraser, Daniel G. ; Onken, Jennifer L. ; Negley, Brittany A. ; Sfeir, Jad G. ; Ogrodnik, Mikolaj B. ; Hachfeld, Christine M. ; LeBrasseur, Nathan K ; Drake, Matthew M ; Pignolo, Robert ; Pirtskhalava, Tamar ; Tchkonia, Tamara ; Oursler, Merry Jo ; Kirkland, James L ; Khosla, Sundeep. / Targeting cellular senescence prevents age-related bone loss in mice. In: Nature Medicine. 2017 ; Vol. 23, No. 9. pp. 1072-1079.
@article{8cf3df4364c3447cbea76e0a7c2c1483,
title = "Targeting cellular senescence prevents age-related bone loss in mice",
abstract = "Aging is associated with increased cellular senescence, which is hypothesized to drive the eventual development of multiple comorbidities. Here we investigate a role for senescent cells in age-related bone loss through multiple approaches. In particular, we used either genetic (i.e., the INK-ATTAC 'suicide' transgene encoding an inducible caspase 8 expressed specifically in senescent cells) or pharmacological (i.e., 'senolytic' compounds) means to eliminate senescent cells. We also inhibited the production of the proinflammatory secretome of senescent cells using a JAK inhibitor (JAKi). In aged (20-to 22-month-old) mice with established bone loss, activation of the INK-ATTAC caspase 8 in senescent cells or treatment with senolytics or the JAKi for 2-4 months resulted in higher bone mass and strength and better bone microarchitecture than in vehicle-Treated mice. The beneficial effects of targeting senescent cells were due to lower bone resorption with either maintained (trabecular) or higher (cortical) bone formation as compared to vehicle-Treated mice. In vitro studies demonstrated that senescent-cell conditioned medium impaired osteoblast mineralization and enhanced osteoclast-progenitor survival, leading to increased osteoclastogenesis. Collectively, these data establish a causal role for senescent cells in bone loss with aging, and demonstrate that targeting these cells has both anti-resorptive and anabolic effects on bone. Given that eliminating senescent cells and/or inhibiting their proinflammatory secretome also improves cardiovascular function, enhances insulin sensitivity, and reduces frailty, targeting this fundamental mechanism to prevent age-related bone loss suggests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbidities.",
author = "Joshua Farr and Ming Xu and Megan Weivoda and Monroe, {David G} and Fraser, {Daniel G.} and Onken, {Jennifer L.} and Negley, {Brittany A.} and Sfeir, {Jad G.} and Ogrodnik, {Mikolaj B.} and Hachfeld, {Christine M.} and LeBrasseur, {Nathan K} and Drake, {Matthew M} and Robert Pignolo and Tamar Pirtskhalava and Tamara Tchkonia and Oursler, {Merry Jo} and Kirkland, {James L} and Sundeep Khosla",
year = "2017",
month = "9",
day = "1",
doi = "10.1038/nm.4385",
language = "English (US)",
volume = "23",
pages = "1072--1079",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Targeting cellular senescence prevents age-related bone loss in mice

AU - Farr, Joshua

AU - Xu, Ming

AU - Weivoda, Megan

AU - Monroe, David G

AU - Fraser, Daniel G.

AU - Onken, Jennifer L.

AU - Negley, Brittany A.

AU - Sfeir, Jad G.

AU - Ogrodnik, Mikolaj B.

AU - Hachfeld, Christine M.

AU - LeBrasseur, Nathan K

AU - Drake, Matthew M

AU - Pignolo, Robert

AU - Pirtskhalava, Tamar

AU - Tchkonia, Tamara

AU - Oursler, Merry Jo

AU - Kirkland, James L

AU - Khosla, Sundeep

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Aging is associated with increased cellular senescence, which is hypothesized to drive the eventual development of multiple comorbidities. Here we investigate a role for senescent cells in age-related bone loss through multiple approaches. In particular, we used either genetic (i.e., the INK-ATTAC 'suicide' transgene encoding an inducible caspase 8 expressed specifically in senescent cells) or pharmacological (i.e., 'senolytic' compounds) means to eliminate senescent cells. We also inhibited the production of the proinflammatory secretome of senescent cells using a JAK inhibitor (JAKi). In aged (20-to 22-month-old) mice with established bone loss, activation of the INK-ATTAC caspase 8 in senescent cells or treatment with senolytics or the JAKi for 2-4 months resulted in higher bone mass and strength and better bone microarchitecture than in vehicle-Treated mice. The beneficial effects of targeting senescent cells were due to lower bone resorption with either maintained (trabecular) or higher (cortical) bone formation as compared to vehicle-Treated mice. In vitro studies demonstrated that senescent-cell conditioned medium impaired osteoblast mineralization and enhanced osteoclast-progenitor survival, leading to increased osteoclastogenesis. Collectively, these data establish a causal role for senescent cells in bone loss with aging, and demonstrate that targeting these cells has both anti-resorptive and anabolic effects on bone. Given that eliminating senescent cells and/or inhibiting their proinflammatory secretome also improves cardiovascular function, enhances insulin sensitivity, and reduces frailty, targeting this fundamental mechanism to prevent age-related bone loss suggests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbidities.

AB - Aging is associated with increased cellular senescence, which is hypothesized to drive the eventual development of multiple comorbidities. Here we investigate a role for senescent cells in age-related bone loss through multiple approaches. In particular, we used either genetic (i.e., the INK-ATTAC 'suicide' transgene encoding an inducible caspase 8 expressed specifically in senescent cells) or pharmacological (i.e., 'senolytic' compounds) means to eliminate senescent cells. We also inhibited the production of the proinflammatory secretome of senescent cells using a JAK inhibitor (JAKi). In aged (20-to 22-month-old) mice with established bone loss, activation of the INK-ATTAC caspase 8 in senescent cells or treatment with senolytics or the JAKi for 2-4 months resulted in higher bone mass and strength and better bone microarchitecture than in vehicle-Treated mice. The beneficial effects of targeting senescent cells were due to lower bone resorption with either maintained (trabecular) or higher (cortical) bone formation as compared to vehicle-Treated mice. In vitro studies demonstrated that senescent-cell conditioned medium impaired osteoblast mineralization and enhanced osteoclast-progenitor survival, leading to increased osteoclastogenesis. Collectively, these data establish a causal role for senescent cells in bone loss with aging, and demonstrate that targeting these cells has both anti-resorptive and anabolic effects on bone. Given that eliminating senescent cells and/or inhibiting their proinflammatory secretome also improves cardiovascular function, enhances insulin sensitivity, and reduces frailty, targeting this fundamental mechanism to prevent age-related bone loss suggests a novel treatment strategy not only for osteoporosis, but also for multiple age-related comorbidities.

UR - http://www.scopus.com/inward/record.url?scp=85029078668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029078668&partnerID=8YFLogxK

U2 - 10.1038/nm.4385

DO - 10.1038/nm.4385

M3 - Article

C2 - 28825716

AN - SCOPUS:85029078668

VL - 23

SP - 1072

EP - 1079

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -